
SANO GENETICS LTD

UNAUDITED

FINANCIAL STATEMENTS

INFORMATION FOR FILING WITH THE REGISTRAR

FOR THE YEAR ENDED 28 FEBRUARY 2020

SANO GENETICS LTD

CONTENTS

	Page
Balance Sheet	1 - 2
Notes to the Financial Statements	3 - 6

SANO GENETICS LTD
REGISTERED NUMBER: 10636359

BALANCE SHEET
AS AT 28 FEBRUARY 2020

	Note	2020 £	2019 £
CURRENT ASSETS			
Stocks		16,625	5,374
Debtors: amounts falling due within one year	4	88,009	25,552
Cash at bank and in hand		45,015	349,376
		<u>149,649</u>	<u>380,302</u>
Creditors: amounts falling due within one year	5	(59,975)	(10,832)
NET CURRENT ASSETS		89,674	369,470
TOTAL ASSETS LESS CURRENT LIABILITIES		89,674	369,470
NET ASSETS		89,674	369,470
CAPITAL AND RESERVES			
Called up share capital	6	133	133
Share premium account		500,709	500,709
Profit and loss account		(411,168)	(131,372)
		<u>89,674</u>	<u>369,470</u>

The directors consider that the Company is entitled to exemption from audit under section 477 of the Companies Act 2006 and members have not required the Company to obtain an audit for the year in question in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime and in accordance with the provisions of FRS 102 Section 1A - small entities.

The financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The Company has opted not to file the profit and loss account or the directors' report in accordance with provisions applicable to companies subject to the small companies' regime.

SANO GENETICS LTD
REGISTERED NUMBER: 10636359

BALANCE SHEET (CONTINUED)
AS AT 28 FEBRUARY 2020

The financial statements were approved and authorised for issue by the board and were signed on its behalf by:

P Short
Director

Date: 22 October 2020

The notes on pages 3 to 6 form part of these financial statements.

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 28 FEBRUARY 2020

1. GENERAL INFORMATION

Sano Genetics Ltd is a private company limited by shares and incorporated in England and Wales. Its registered office address is Salisbury House, Station Road, Cambridge, CB1 2LA. Its principal place of business is WeWork, 50-60 Station Road, Cambridge, CB1 2JH.

2. ACCOUNTING POLICIES

2.1 BASIS OF PREPARATION OF FINANCIAL STATEMENTS

The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with Section 1A of Financial Reporting Standard 102, the Financial Reporting Standard applicable in the UK and the Republic of Ireland and the Companies Act 2006.

The following principal accounting policies have been applied:

2.2 GOING CONCERN

In light of the on-going global health crisis caused by COVID-19 the directors have assessed the potential impact that a period of interrupted trading would bring. The directors have put in place contingency plans to reduce the cost base further if required, should the position worsen for a prolonged period of time, and the Company has raised significant investment from the issue of new shares subsequent to the year end. Accordingly the directors continue to adopt the going concern basis of accounting in preparing these financial statements.

2.3 TURNOVER

Turnover comprises revenue recognised by the Company in respect of DNA kits and services supplied during the year, exclusive of Value Added Tax. Revenue is recognised as the fair value of the consideration received or receivable and is recognised in the period in which the DNA kits and the services are supplied.

2.4 STOCKS

Stocks are stated at the lower of cost and net realisable value, being the estimated selling price less costs to complete and sell. Cost is based on the cost of purchase and includes all direct costs.

At each balance sheet date, stocks are assessed for impairment. If stock is impaired, the carrying amount is reduced to its selling price less costs to complete and sell. The impairment loss is recognised immediately in profit or loss.

2.5 DEBTORS

Short term debtors are measured at transaction price, less any impairment.

2.6 CASH AND CASH EQUIVALENTS

Cash is represented by cash in hand and deposits with financial institutions repayable without penalty on notice of not more than 24 hours. Cash equivalents are highly liquid investments that mature in no more than three months from the date of acquisition and that are readily convertible to known amounts of cash with insignificant risk of change in value.

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 28 FEBRUARY 2020

2. ACCOUNTING POLICIES (CONTINUED)

2.7 CREDITORS

Short term creditors are measured at the transaction price. Other financial liabilities are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method.

2.8 TAXATION

Tax is recognised in the Profit and Loss Account, except that a charge attributable to an item of income and expense recognised as other comprehensive income or to an item recognised directly in equity is also recognised in other comprehensive income or directly in equity respectively.

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the balance sheet date in the countries where the Company operates and generates income.

Deferred tax balances are recognised in respect of all timing differences that have originated but not reversed by the Balance Sheet date, except that:

- The recognition of deferred tax assets is limited to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits; and

- Any deferred tax balances are reversed if and when all conditions for retaining associated tax allowances have been met.

Deferred tax balances are not recognised in respect of permanent differences. Deferred tax is determined using tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

2.9 FOREIGN CURRENCY TRANSLATION

Functional and presentation currency

The Company's functional and presentational currency is GBP.

Transactions and balances

Foreign currency transactions are translated into the functional currency using the spot exchange rates at the dates of the transactions.

At each period end foreign currency monetary items are translated using the closing rate. Non-monetary items measured at historical cost are translated using the exchange rate at the date of the transaction and non-monetary items measured at fair value are measured using the exchange rate when fair value was determined.

Foreign exchange gains and losses resulting from the settlement of transactions and from the translation at period-end exchange rates of monetary assets and liabilities denominated in foreign currencies are recognised in the Profit and Loss Account except when deferred in other comprehensive income as qualifying cash flow hedges.

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 28 FEBRUARY 2020**

2. ACCOUNTING POLICIES (CONTINUED)

2.10 PENSIONS

Defined contribution pension plan

The Company operates a defined contribution plan for its employees. A defined contribution plan is a pension plan under which the Company pays fixed contributions into a separate entity. Once the contributions have been paid the Company has no further payment obligations.

The contributions are recognised as an expense in the Profit and Loss Account when they fall due. Amounts not paid are shown in accruals as a liability in the Balance Sheet. The assets of the plan are held separately from the Company in independently administered funds.

2.11 OPERATING LEASES

Rentals paid under operating leases are charged to the Profit and Loss Account on a straight line basis over the lease term.

2.12 RESEARCH AND DEVELOPMENT

Research and development costs are recognised in the Profit and Loss Account in the period in which they are incurred.

2.13 GRANT INCOME

Grant income is recognised in the Profit and Loss Account as the related expenditure is incurred.

3. EMPLOYEES

The average monthly number of employees, including directors, during the year was 7 (2019 - 4).

4. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

	2020	2019
	£	£
Other debtors	57,351	20,442
Prepayments and accrued income	30,658	5,110
	88,009	25,552

SANO GENETICS LTD

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 28 FEBRUARY 2020**

5. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

	2020	2019
	£	£
Other loans	40,000	-
Trade creditors	8,258	6,021
Other taxation and social security	6,797	794
Other creditors	1,597	895
Accruals and deferred income	3,323	3,122
	<u>59,975</u>	<u>10,832</u>

Other creditors include contributions of £1,097 (2019 - £395) payable to the Company's defined contribution pension scheme at the balance sheet date.

6. SHARE CAPITAL

	2020	2019
	£	£
ALLOTTED, CALLED UP AND FULLY PAID		
1,000,000 Ordinary shares of £0.0001 each	100	100
329,218 A Ordinary shares of £0.0001 each	33	33
	<u>133</u>	<u>133</u>

7. COMMITMENTS UNDER OPERATING LEASES

At 28 February 2020 the Company had future minimum lease payments under non-cancellable operating leases as follows:

	2020	2019
	£	£
Not later than 1 year	11,970	13,470
	<u>11,970</u>	<u>13,470</u>

This document was delivered using electronic communications and authenticated in accordance with the registrar's rules relating to electronic form, authentication and manner of delivery under section 1072 of the Companies Act 2006.